PASADENA: A Phase 2 study to evaluate the safety and efficacy of prasinezumab in early Parkinson’s disease; Part 1 Week-52 results
Objective: Evaluate efficacy and safety of prasinezumab following 52 weeks of treatment in participants with early Parkinson’s disease (PD). Background: Prasinezumab is a humanized monoclonal…Researches on the correlation between wearable device data and UPDRS scores in patients with Parkinson’s disease
Objective: To collect spatiotemporal parameter information of motor symptoms in patients with Parkinson's disease (PD) using wearable device, and analyze its correlation with the Unified…Randomized, placebo-controlled study investigating the safety, pharmacokinetics and efficacy of inhaled apomorphine in Parkinson’s disease patients
Objective: To evaluate the safety, pharmacokinetics (PK) and efficacy of single-dose apomorphine inhalation in PD patients. Background: Apomorphine is a dopamine agonist, approved for treating…Refining Knowledge on the Treatment of Pisa Syndrome with Botulinum Toxin
Objective: To analyze the efficacy of botulinum toxin (BoNT) in cases of pisa syndrome (PS) associated with Parkinson's disease (PD) targeting paraspinal muscles ipsilateral to…Deep Brain Stimulation as the Only Advanced Therapy Available in the Dominican Rebublic, Report ot Two Cases in Centro Cardio Neuro Oftalmologico Y Transplante (Cecanot)
Objective: To describe the evolution of two cases of Parkinson's disease treated with deep brain stimulation in CECANOT. Background: Parkinson's disease is the second most…Impact of dopamine 2/3 receptor agonists on the phenomenology of L-DOPA-induced dyskinesia in patients with Parkinson’s disease
Objective: To investigate possible differences in phenomenology and temporal profile of dyskinesias in patients with Parkinson’s disease (PD) after challenge doses with levodopa alone or…Anti-parkinson effect of natural L-DOPA containing drug Mucuna pruriens against the rotenone induced rat model of Parkinson’s disease
Objective: The nanoherbaceutical formulation comprising natural L-DOPA from Mucuna pruriens against rotenone caused Parkinson's disease in rats to be prepared and evaluated. Background: Parkinson's disease…Vascular age calculated by pulse wave velocity may help predict the prognosis after Deep brain stimulation surgery in patients with Parkinson’s disease
Objective: We aimed to examine the relationship between pulse wave velocity (PWV) at pre- deep brain stimulation (DBS) stage and symptoms change at post-DBS stage.…Low dose Cabergoline for freezing of gait in advanced Parkinson’s disease – you can have your cake and eat it too!
Objective: To evaluate efficacy of cabergoline for treating FOG in advanced IPD. Background: FOG is a major cause of disability in advanced IPD. FOG responds…Distribution of intranasal hNSCs in a mouse model of MPTP-induced Parkinson’s disease
Objective: We aimed to map the distribution of human neural stem cells (hNSCs) in the brain and peripheral tissues after intranasal administration in a mouse…
- « Previous Page
- 1
- …
- 42
- 43
- 44
- 45
- 46
- …
- 149
- Next Page »